877P Exploratory efficacy and translational results from the safety run in of AHEAD-MERIT, a phase II trial of first line pembrolizumab plus the fixed-antigen cancer vaccine BNT113 in advanced HPV16+ HNSCC

Nabil F. Saba, K. Klinghammer, E. Castelluci, A.D. Colevas, Tomasz Rutkowski, D. Thurner, U. Müller-Richter, Massimo Di Maïo, Jasmaninder Singh Grewal, C.H.H. Ottensmeier, J. Dias, Huyuan Yang, Rishub K. Das, J. Furlanetto, A-K. Herzfeldt, M-C. Kühnle, Alexander Ulges, J U Alles, Ö. Türeci, Uğur Şahin